Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine

20260 citationsJournal Article

Authors

Edoardo Caronna · Universitat Autònoma de Barcelona

Rut Mas-de-les-Valls · Universitat Autònoma de Barcelona

Gabriella Egeo · Vita-Salute San Raffaele University

M. Millán Vázquez · Hospital Universitario Virgen del Rocío

Candela Nieves-Castellanos · Hospital Universitari i Politècnic La Fe

Leonardo Portocarrero-Sánchez · Hospital Universitario La Paz

Gloria Vaghi

Abstract

This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.

Topics & Keywords

Migraine and Headache Studies Autoimmune Neurological Disorders and Treatments Vestibular and auditory disorders

Publication Details

Published in: Neurology

Volume 106, Issue 4, pp. e214659-e214659

DOI: 10.1212/wnl.0000000000214659

Field-Weighted Citation Impact: 0.00

Command Palette

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine

Authors

Abstract

Topics & Keywords

Publication Details